Inhibikase TherapeuticsIKT +1.60%33 Quick Ratio is 30.14 as of Mar. 2026, which is 299% above its 10-year median of 7.56. GuruFocus rates IKT with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,413 Biotechnology companies, Inhibikase Therapeutics ranks better than 96.53% on this metric.
Inhibikase Therapeutics has a quick ratio of 30.14. It generally indicates good short-term financial strength.
The historical rank and industry rank for Inhibikase Therapeutics's Quick Ratio or its related term are showing as below:
IKT'
s Quick Ratio Range Over the Past 10 Years
Min: 0.01 Med: 7.56 Max: 30.14
Current: 30.14
During the past 8 years, Inhibikase Therapeutics's highest Quick Ratio was 30.14. The lowest was 0.01. And the median was 7.56.
IKT's Quick Ratio is ranked better than 96.53% of 1413
companies
in the Biotechnology industry
Industry Median: 3.6
vs IKT: 30.14
Inhibikase Therapeutics (NAS:IKT) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Inhibikase Therapeutics Quick Ratio Related Terms
Inhibikase Therapeutics Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Inhibikase Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibikase Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Inhibikase Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Inhibikase Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibikase Therapeutics (IKT) has a Quick Ratio of 30.14 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Inhibikase Therapeutics and its competitors. This is 299% above median its historical median of 7.56. Over the past decade, Inhibikase Therapeutics' Quick Ratio has ranged from 0.01 to 30.14. According to the industry distribution chart, Inhibikase Therapeutics ranks #49 out of 1413 companies in the Biotechnology industry, placing it in the top 3.5%.
Is Inhibikase Therapeutics' Quick Ratio too high?
Inhibikase Therapeutics' current Quick Ratio of 30.14 is 299% above median its 10-year median of 7.56. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 30.14. The Biotechnology industry median Quick Ratio is 3.60. Inhibikase Therapeutics' value of 30.14 is 737.2% above this industry median. Based on the distribution chart, Inhibikase Therapeutics ranks #49 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Inhibikase Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Inhibikase Therapeutics' Quick Ratio compare to NKTX and CAMP?
According to the Biotechnology industry distribution chart, Inhibikase Therapeutics ranks #49 out of 1413 companies for Quick Ratio. This places Inhibikase Therapeutics in the top 4% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Inhibikase Therapeutics' value of 30.14 is 737.2% above this benchmark. Historically, Inhibikase Therapeutics' own Quick Ratio has ranged from 0.01 to 30.14 over the past decade. While the company's 10-year median is 7.56 vs. the industry median of 3.60, Inhibikase Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inhibikase Therapeutics's current Quick Ratio of 30.14 is 737.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Inhibikase Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inhibikase Therapeutics's current Quick Ratio is 30.14, which is 299% above median its own 10-year median of 7.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibikase Therapeutics stock overvalued right now?
Inhibikase Therapeutics (IKT) has a current Quick Ratio of 30.14. The current Quick Ratio is 30.14, which is 299% above median its 10-year median of 7.56 and 737.2% above the Biotechnology industry median of 3.60. Inhibikase Therapeutics' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Inhibikase Therapeutics (IKT), the current Quick Ratio is 30.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
33GF Score
Get the complete analysis for IKT
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IKT has been successfully added to your 
